DOCSLIB.ORG

Epiphora 16-9

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Epiphora 16-9 EPIPHORA: A STRATEGY FOR SOLVING THE Maple Grove Fridley Maplewood COMMON COMPLAINT JORDAN KEITH, OD, FAAO MINNEAPOLIS, MN Greg Kraupa, OD Steve Nauman, OD Mitch Albers, OD Brad Richter, OD Tina McCarty, OD Ashley Herde, OD Jordan Keith, OD OBJECTIVES • RECALL NORMAL ANATOMY OF TEAR PRODUCTION AND DRAINAGE • IDENTIFY CAUSES OF OVERPRODUCTION OF TEARS • IDENTIFY CAUSES OF REDUCED DRAINAGE OF TEARS • LIST TREATMENT OPTIONS TO PREVENT EPIPHORA Meibomian glands NASOLACRIMAL DRAINAGE SYSTEM Lipid Zeiss/Moll Reflex MLG Aqueous Emotional ALG Maintenance Mucin Goblet cells Cornea 1 Dry Eye Overproduction Exposure “Dry eye is a multifactorial disease of the Conjunctivochalasis tears and ocular surface that results in Epiphora symptoms of discomfort, visual disturbance, Eyelids and tear film instability with potential damage to the ocular surface. It is Punctual stenosis Poor drainage accompanied by increased osmolarity of the Canaliculitis tear film and inflammation of the ocular surface.” Dacryocystitis Lemp MA. The Definition and Classification of Dry Eye Disease. DEWS. The Ocular Surface. 2007; 5(2) NLDO TEARLAB CAUSATIVE MECHANISMS TEAR HYPEROSMOLARITY TEAR FILM INSTABILITY • RESULTS IN AN • CAN ARISE SECONDARY TO INFLAMMATORY CASCADE TEAR HYPEROSMOLARITY THAT DAMAGES THE OUTER OR CAN BE THE INITIATING SURFACE AND RELEASES EVENT IN THE DISEASE INFLAMMATORY MEDIATORS PROCESS INTO THE TEARS Lemp MA. The Definition and Classification of Dry Eye Disease. DEWS. The Ocular Surface. 2007; 5(2) Primary Sjogrens Secondary NAFL STAINING Aqueous Tear Primary lacrimal Deficiency (ADDE) gland deficiency • TBUT • LACRIMAL LAKE Secondary lacrimal gland deficiency • CORNEA DISEASE Dry Eye Non-Sjogrens Obstruction of • SEVERITY lacrimal gland ducts • JONES 1 Intrinsic Reflex Evaporative (EDE) hyposecretion Extrinsic Lemp MA. The Definition and Classification of Dry Eye Disease. DEWS. The Ocular Surface. 2007; 5(2) 2 LISSAMINE SJOGREN’S SYNDROME NEW GREEN DIAGNOSTIC CRITERIA (2 OF 3) STAINING Positive serum anti-SSA and/or anti-SSB OR [positive RF • SEVERITY AND ANA ≥ 1:320] Ocular staining score (OSS) ≥ 3 Presence of focal lymphocytic sialadenitis with focus score ≥ 1 focus/4 mm2 in a labial salivary gland biopsy Shiboski SC et al. American College of Rheumatology Classification Criteria for Sjögren’s Syndrome: SICCA Cohort. Arthritis Care Res (Hoboken). 2012 April ; 64(4): 475–487 LISSAMINE GREEN STAINING 1 2 3 Whitcher JP et al. Figure 2. Am J Ophthalmol. 2010 March ; 149(3): 405–415 Whitcher JP et al. Am J Ophthalmol. 2010 March ; 149(3): 405–415 FLUORESCEIN STAINING CONSECUTIVE PATIENTS WITH “PRIMARY” SS (N=163) 98% history of dry eye for average 10.4 years 25% extraglandular ocular manifestations 1 3 5 13% vision-threatening findings 42% extraglandular systemic manifestations Akpek EK et al. Ocular and systemic morbidity in a longitudinal cohort of Sjögren's syndrome. Whitcher JP et al. Am J Ophthalmol. 2010 March ; 149(3): 405–415 Ophthalmology. 2015 Jan;122(1):56-61 3 ® Observational Study Medicine OPEN Predicting the risk for lymphoma development in Sjogren syndrome An easy tool for clinical use Sjogern’s Syndrome has been shown to be an Sofia Fragkioudaki (MD)a, Clio P. Mavragani (MD)a,b,c,∗, Haralampos M. Moutsopoulos (MD, FACP, FRCP, independent risk factor for the development of MACR)b,c Abstract The heightened risk of non-Hodgkin lymphoma (NHL) development in primary Sjogren syndrome (SS) is well established. Several adverse clinical and laboratoryPatients predictors presenting have been described. with In theindependent current work, we aimed risk to formulate factors a predictive score for NHL non-Hodgkin’s lymphoma (NHL) development, based on clinical, serological, and histopathological findings at the time of SS diagnosis. In the present case–control study of 381 primary SSidentified patients and 92 and primary their SS patients risk with of concomitant NHL NHL,development: clinical, serological, and histopathological variables at the time of SS diagnosis were retrospectively recorded. For the identification of predictors for NHL development univariate• 2 andrisk multivariate factors models had were constructed.a 3.8% Salivary probability gland enlargement (SGE), lymphadenopathy, Raynaud phenomenon, anti-Ro/SSA or/and anti-La/SSB autoantibodies, rheumatoid factor (RF) positivity, monoclonal gammopathy, and C4 hypocomplementemia• 3 to 6 risk were factors shown to had be independent a 39.9% predictors probability for NHL development. (OR On (95%CI): the basis of the 16.6 number of Afflicting about 5% independent risk factors identified, a predictive risk score for NHL development was formulated. Thus, patients presenting with 2 risk factors[6.5 had– a42.5], 3.8% probability P < of NHL0.05 development,) those with 3 to 6 risk factors 39.9% (OR (95%CI): 16.6 [6.5–42.5], P<0.05), while in the presence of all 7 risk factors the corresponding probability reached 100% (OR [95%CI]: 210.0 [10.0–4412.9], P < 0.0001).• All In conclusion,7 risk anfactors easy to use the diagnostic corresponding scoring tool for NHL development probability in the context reached of SS is presented. 100% This model is Estimated to be 7-19 fold higher risk compared to general highly significant for the design of early therapeutic interventions in high risk SS patients for NHL development. Abbreviations:(OR [95%CI]:MALT = mucosa 210.0 associated [10.0 lymphoid– tissue,4412.9], MSG = minor P< salivary 0.0001 gland, NHL = non-Hodgkin lymphoma, PNS = population peripheral nervous system, RF = rheumatoid factor, SGE = salivary gland enlargement, SS = Sjogren syndrome. Keywords: adverse predictors,Fragkioudaki non-Hodgkin lymphoma, et al. Sjogren Medicine. syndrome 2016 95:25 1. Introduction Although mucosa associated lymphoid tissue (MALT) mainly in the salivary glands is the prominent histological lymphoma Sjogren syndrome (SS) is a common systemic autoimmune disease type with a 1000-fold increased risk[4] among primary SS usually confined in the exocrine glands (mainly salivary and Fragkioudaki et al. Medicine. 2016 95:25 patients,[2,10] more aggressive subtypes including diffuse large lachrymal), leading to desiccation of oral and ocular mucosal B-cell lymphomas can also occur.[2,11] tissues. Nevertheless, systemic manifestations can arise in a Lymphomagenesis in the setting of autoimmunity and proportion of SS individuals[1] and B-cell non-Hodgkin lympho- particularly of SS is considered a multifactorial process, not ma (NHL) development represents a severe complication, entirely elucidated yet. Genetic aberrations, including chromo- afflicting approximately 5% of patients.[2] The risk of NHL somal translocations,[12] mutations of the tumor suppressor gene occurrence in the setting of SS, the highest among systemic p53,[13] and polymorphisms of molecules with regulatory role in autoimmune diseases,[3,4] has been previously estimated to be both innate and adaptive immune activation pathways[14,15] have 7- to 19-fold higher compared to the general population.[3–9] been so far implicated. Moreover, according to previous studies, clinical features at disease presentation, such as persistent salivary Editor: Qinhong Zhang. gland enlargement (SGE)[16] and palpable purpura,[16,17] labora- SF and CPM contributed equally to this work. tory abnormalities, like lymphopenia, monoclonal type II The authors have no funding and conflicts of interest to disclose. cryoglobulinemia, and hypocomplementemia[16–18] as well as Supplemental Digital Content is available for this article. intense lymphocytic infiltrations[19] and germinal center forma- [20] a Department of Physiology, b Department of Pathophysiology, c Joint Academic tion in minor salivary gland (MSG) biopsies, have been Rheumatology Program, School of Medicine, National and Kapodistrian identified as adverse predictors for SS-related NHL development. University of Athens, Athens, Greece. As a result, at their first evaluation, SS patients can be classified ∗ Correspondence: Clio P. Mavragani, Department of Physiology, School of into separate subsets with distinct likelihood for lymphoma Medicine, National and Kapodistrian University of Athens, M. Asias 75, 11527 development. Athens, Greece (e-mail: [email protected]). The current study aimed to create a predictive tool in Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. This is an open access article distributed under the Creative Commons clinical practice for SS-related NHL development, based Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and on clinical, hematological, serological, and histopathological reproduction in any medium, provided the original work is properly cited. features, observed early at disease diagnosis. Prompt diagnosis Medicine (2016) 95:25(e3766) would allow early therapeutic intervention with the ultimate Received: 8 December 2015 / Received in final form: 25 April 2016 / Accepted: goal to decelerate the progression of benign to malignant 29 April 2016 lymphoproliferation. http://dx.doi.org/10.1097/MD.0000000000003766 1 35% EDE Dry 30% 10% Neither Eye ADDE Disease DRY EYE TREATMENT 25% EDE & ADDE Lemp MA. Cornea. 2012 May;31(5):472-8 OBESE MALE/RED WATERING EYES EVERY FLOPPY EYELID SYNDROME MORNING • MOST COMMON IN OBESE MALES WITH SLEEP APNEA • 5.7% (N=12/209) PATIENTS WITH SLEEP APNEA HAVE NTG Lin PW et al. J Glaucoma. 2011; 20(9): 553-8 4 LACRIMAL LAKE DISRUPTION CONJUNCTIVOCHALASIS • OFTEN OVERLOOKED • TWO MECHANISMS FOR CAUSING EPIPHORA 1) MORE COMMON: INTERFERENCE BY THE REDUNDANT CONJUNCTIVA WITH
Load more

Recommended publications
  • Low Level Light Therapy for the Treatment of Recalcitrant Chalazia: a Sample Case Summary
    Clinical Ophthalmology Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Low level light therapy for the treatment of recalcitrant chalazia: a sample case summary This article was published in the following Dove Press journal: Clinical Ophthalmology Karl Stonecipher1 Purpose: To evaluate the effects of low-level light therapy (LLLT) on the resolution of Richard Potvin 2 recalcitrant chalazia. Patients and Methods: This was a single-site retrospective chart review of patients with 1Physicians Protocol, Greensboro, NC, USA; 2Science in Vision, Akron, NY, USA chalazia, all of whom were unresponsive to previous pharmaceutical therapy or surgical intervention, who received a 15 min LLLT treatment in conjunction with a standard phar- maceutical regimen. A second treatment was applied 24 hrs to as late as 2 months if there was no evidence of progression of resolution in appearance. Results: A total of 26 eyes of 22 patients with relevant history and treatment were reviewed, all with a history of prior pharmaceutical treatment for their chalazia. After a single 15 min LLLT treatment, followed by a standard pharmaceutical regimen, 46% of eyes (12/26) showed resolution of their chalazia. Resolution was noted from 3 days to one-month post- treatment. With a second treatment, the chalazia resolved in 92% of eyes (24/26). Only two For personal use only. eyes of the 26 (8%) required incision and curettage after LLLT treatment. Conclusion: The use of LLLT for the treatment of recalcitrant chalazia appears to be beneficial in patients who have failed topical and/or systemic therapy, significantly reducing the likelihood of requiring surgical intervention.
    [Show full text]
  • Differentiate Red Eye Disorders
    Introduction DIFFERENTIATE RED EYE DISORDERS • Needs immediate treatment • Needs treatment within a few days • Does not require treatment Introduction SUBJECTIVE EYE COMPLAINTS • Decreased vision • Pain • Redness Characterize the complaint through history and exam. Introduction TYPES OF RED EYE DISORDERS • Mechanical trauma • Chemical trauma • Inflammation/infection Introduction ETIOLOGIES OF RED EYE 1. Chemical injury 2. Angle-closure glaucoma 3. Ocular foreign body 4. Corneal abrasion 5. Uveitis 6. Conjunctivitis 7. Ocular surface disease 8. Subconjunctival hemorrhage Evaluation RED EYE: POSSIBLE CAUSES • Trauma • Chemicals • Infection • Allergy • Systemic conditions Evaluation RED EYE: CAUSE AND EFFECT Symptom Cause Itching Allergy Burning Lid disorders, dry eye Foreign body sensation Foreign body, corneal abrasion Localized lid tenderness Hordeolum, chalazion Evaluation RED EYE: CAUSE AND EFFECT (Continued) Symptom Cause Deep, intense pain Corneal abrasions, scleritis, iritis, acute glaucoma, sinusitis, etc. Photophobia Corneal abrasions, iritis, acute glaucoma Halo vision Corneal edema (acute glaucoma, uveitis) Evaluation Equipment needed to evaluate red eye Evaluation Refer red eye with vision loss to ophthalmologist for evaluation Evaluation RED EYE DISORDERS: AN ANATOMIC APPROACH • Face • Adnexa – Orbital area – Lids – Ocular movements • Globe – Conjunctiva, sclera – Anterior chamber (using slit lamp if possible) – Intraocular pressure Disorders of the Ocular Adnexa Disorders of the Ocular Adnexa Hordeolum Disorders of the Ocular
    [Show full text]
  • Ocular Photography - External (L34393)
    Local Coverage Determination (LCD): Ocular Photography - External (L34393) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor Name Contract Type Contract Number Jurisdiction State(s) CGS Administrators, LLC MAC - Part A 15101 - MAC A J - 15 Kentucky CGS Administrators, LLC MAC - Part B 15102 - MAC B J - 15 Kentucky CGS Administrators, LLC MAC - Part A 15201 - MAC A J - 15 Ohio CGS Administrators, LLC MAC - Part B 15202 - MAC B J - 15 Ohio Back to Top LCD Information Document Information LCD ID Original Effective Date L34393 For services performed on or after 10/01/2015 Original ICD-9 LCD ID Revision Effective Date L31880 For services performed on or after 10/01/2018 Revision Ending Date LCD Title N/A Ocular Photography - External Retirement Date Proposed LCD in Comment Period N/A N/A Notice Period Start Date Source Proposed LCD N/A N/A Notice Period End Date AMA CPT / ADA CDT / AHA NUBC Copyright Statement N/A CPT only copyright 2002-2018 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. The Code on Dental Procedures and Nomenclature (Code) is published in Current Dental Terminology (CDT).
    [Show full text]
  • Epiphora During the First Year of Life
    Eye (1991) 5, 596--600 Epiphora During the First Year of Life C. J. MACEWEN and J. D. H. YOUNG Dundee Summary A cohort of 4,792 infants was observed in order to determine the incidence and natu­ ral history of epiphora during the first year of life. Evidence of defective lacrimal drainage was present in 964 (20%) at some time during the year. 9S�/o became symp­ tomatic during the first month of life. Spontaneous remission occurred throughout the year and 96% had resolved before the age of one. This study provides no evidence to support probing before the age of one year. Infants with epiphora are a common problem haps the most reliable estimate of the inci­ in clinical ophthalmology. It is generally dence is 6%. This comes from a follow-up accepted that the condition is the result of a study of 200 consecutive, unselected newborn congenital abnormality of the lacrimal drain­ infants.7 age system, in the form of a membranous Information on the rate of spontaneous obstruction at the lower end of the naso-lac­ remission is also limited. The studies that are rimal duct (NLD). I In addition it is recognised available were based on small clinic popula­ that there is a high rate of spontaneous resol­ tions, referred for treatment of their epiphora ution.2•3 However, despite it's frequency, rela­ and probing was usually undertaken in a tively little is known about the incidence or number of cases before the end of the year.2,3 natural history of epiphora in young children.
    [Show full text]
  • Olivia Steinberg ICO Primary Care/Ocular Disease Resident American Academy of Optometry Residents Day Submission
    Olivia Steinberg ICO Primary Care/Ocular Disease Resident American Academy of Optometry Residents Day Submission The use of oral doxycycline and vitamin C in the management of acute corneal hydrops: a case comparison Abstract- We compare two patients presenting to clinic with an uncommon complication of keratoconus, acute corneal hydrops. Management of the patients differs. One heals quickly, while the other has a delayed course to resolution. I. Case A a. Demographics: 40 yo AAM b. Case History i. CC: red eye, tearing, decreased VA x 1 day OS ii. POHx: (+) keratoconus OU iii. PMHx: depression, anxiety, asthma iv. Meds: Albuterol, Ziprasidone v. Scleral CL wearer for approximately 6 months OU vi. Denies any pain OS, denies previous occurrence OU, no complaints OD c. Pertinent Findings i. VA cc (CL’s)- 20/25 OD, 20/200 PH 20/60+2 OS ii. Slit Lamp 1. Inferior corneal thinning and Fleisher ring OD, central scarring OD, 2+ diffuse microcystic edema OS, Descemet’s break OS (photos and anterior segment OCT) 2. 2+ diffuse injection OS 3. D&Q A/C OU iii. Intraocular Pressures: deferred OD due to CL, 9mmHg OS (tonopen) iv. Fundus Exam- unremarkable OU II. Case B a. Demographics: 39 yo AAM b. Case History i. CC: painful, red eye, tearing, decreased VA x 1 day OS ii. POHx: unremarkable iii. PMHx: hypertension iv. Meds: unknown HTN medication v. Wears Soflens toric CL’s OU; reports previous doctor had difficulty achieving proper fit OU; denies diagnosis of keratoconus OU vi. Denies any injury OS, denies previous occurrence OU, no complaints OD c.
    [Show full text]
  • Etiology and Management of Epiphora in the Adult Patient: a Retrospective Study in an Interdisciplinary Epiphora Clinic
    Research Article Journal of Clinical Ophthalmology and Eye Disorders Published: 26 Feb, 2021 Etiology and Management of Epiphora in the Adult Patient: A Retrospective Study in an Interdisciplinary Epiphora Clinic Vincent Q1*, Roxane F1, Aurelie L1 and Nicolas M2 1Department of Ophthalmology, UCLouvain, UCLouvain Catholic University of Louvain, Belgium 2Department of Otorhinolaryngology, UCLouvain, UCLouvain Catholic University of Louvain, Belgium Abstract Background: Epiphora in adults is a frequent ophthalmological condition with multiple etiologies, and requires a multidisciplinary approach for management, diagnosis and treatment, combining ophthalmologists, ENTs, nuclear medicine specialists, radiologists. Few centers possess a truly multi-specialty method for analyzing and treating epiphora in adults. Materials and Methods: We have conducted a retrospective study on 57 patients with a follow-up of 12 months, to examine the different etiologies and treatments in a multidisciplinary epiphora clinic in a tertiary care setting. Patients were systematically examined by an ophthalmologist and an ENT specialist, in addition to a full epiphora clinical workup. If needed, they were then referred for additional examinations in radiology (dacryo cone beam scanner) or scintigraphy. Results: Obstruction at any stage of the lacrimal drainage system was the most common cause of epiphora (48%), followed by ocular surface disease (28%), then eyelid malposition or laxity (26%), and finally functional causes. Regarding treatments, 10.5% (n=6) of patients underwent 3-snip punctoplasty, 8% (n=5) underwent canalicular repermeabilization through sharp catheterization, 21% (n=12) underwent DCR, 42% (n=24) were prescribed lid hygiene or ocular lubrication, 21% OPEN ACCESS (n=12) underwent eyelid surgery through canthopexy, 1% (n=1) had a combined treatment and 19% (n=11) had no treatment.
    [Show full text]
  • Chronic Conjunctivitis
    9/8/2017 Allergan Pharmaceuticals Speaker’s Bureau Bio-Tissue BioDLogics, LLC Katena/IOP Seed Biotech COA Monterey Symposium 2017 Johnson and Johnson Vision Care, Inc. Shire Pharmaceuticals Nicholas Colatrella, OD, FAAO, Dipl AAO, ABO, ABCMO Jeffrey R. Varanelli, OD, FAAO, Dipl ABO, ABCMO Text NICHOLASCOLA090 to 22333 to join Live Text Poll Nicholas Colatrella, OD, FAAO, Dipl AAO, Jeffrey Varanelli, OD, FAAO, Dipl ABO, ABO, ABCMO ABCMO Text NICHOLASCOLA090 to 22333 once to join Then text A, B, C, D, E or write in your answer Live Immediate Accurate Chronic conjunctivitis is one of the most frustrating reasons that patients present to the office (1) Time course Often times patients will seek multiple providers searching for a solution The chronicity of their symptoms is extremely frustrating to the (2) Morphology patient and treating physician alike Some conditions can seriously affect vision and create ocular morbidity (3) Localization of disease process Many of these diseases do not respond to commonly used topical antibiotics, topical steroids, artificial tears, and other treatments for external ocular disease (4) Type of discharge or exudate Our hope during this one-hour lecture is to present a process to help aid in the diagnosis of chronic conjunctivitis help you determine the most likely etiology 1 9/8/2017 Three weeks is the dividing point as it is the upper limit for cases of viral infection and most bacterial infections to resolve without treatment. Acute Conjunctivitis Conjunctivitis that has been present for less than 3 weeks
    [Show full text]
  • Quality of Vision in Eyes with Epiphora Undergoing Lacrimal Passage Intubation
    Quality of Vision in Eyes With Epiphora Undergoing Lacrimal Passage Intubation SHIZUKA KOH, YASUSHI INOUE, SHINTARO OCHI, YOSHIHIRO TAKAI, NAOYUKI MAEDA, AND KOHJI NISHIDA PURPOSE: To investigate visual function and optical PIPHORA, THE MAIN COMPLAINT OF PATIENTS WITH quality in eyes with epiphora undergoing lacrimal passage lacrimal passage obstruction, causes blurred vision, intubation. discomfort, and skin eczema, and may even cause so- E DESIGN: Prospective case series. cial embarrassment. Several studies have assessed the qual- METHODS: Thirty-four eyes of 30 patients with ity of life (QoL) or vision-related QoL of patients suffering lacrimal passage obstruction were enrolled. Before and from lacrimal disorders and the impact of surgical treat- 1 month after lacrimal passage intubation, functional vi- ments on QoL, using a variety of symptom-based question- sual acuity (FVA), higher-order aberrations (HOAs), naires.1–8 According to these studies, epiphora negatively lower tear meniscus, and tear clearance were assessed. affects QoL physically and socially; however, surgical An FVA measurement system was used to examine treatment can improve QoL. Increased tear meniscus changes in continuous visual acuity (VA) over time, owing to inadequate drainage contributes to blurry and visual function parameters such as FVA, visual main- vision.9 However, quality of vision (QoV) has not been tenance ratio, and blink frequency were obtained. fully quantified in eyes with epiphora, and the effects of Sequential ocular HOAs were measured for 10 seconds lacrimal surgery on such eyes are unknown. after the blink using a wavefront sensor. Aberration Dry eye, a clinically significant multifactorial disorder of data were analyzed in the central 4 mm for coma-like, the ocular surface and tear film, may cause visual distur- spherical-like, and total HOAs.
    [Show full text]
  • Vertical Perspective Medical Assistance Program
    Kansas Vertical Perspective Medical Assistance Program December 2006 Provider Bulletin Number 688 General Providers Emergent and Nonemergent Diagnosis Code List Attached is a list of diagnosis codes and whether the Kansas Medical Assistance Program (KMAP) considers the code to be emergent or nonemergent. Providers are responsible for validating whether a particular diagnosis code is covered by KMAP under the beneficiary’s benefit plan and that all program requirements are met. This list does not imply or guarantee payment for listed diagnosis codes. Information about the Kansas Medical Assistance Program as well as provider manuals and other publications are on the KMAP Web site at https://www.kmap-state-ks.us. If you have any questions, please contact the KMAP Customer Service Center at 1-800-933-6593 (in-state providers) or (785) 274-5990 between 7:30 a.m. and 5:30 p.m., Monday through Friday. EDS is the fiscal agent and administrator of the Kansas Medical Assistance Program for the Kansas Health Policy Authority. Page 1 of 347 Emergency Indicators as noted by KMAP: N – Never considered emergent S – Sometimes considered emergent (through supporting medical documentation) Y – Always considered emergent Diagnosis Emergency Diagnosis Code Description Code Indicator 0010 Cholera due to Vibrio Cholerae S 0011 Cholera due to Vibrio Cholerae El Tor S 0019 Unspecified Cholera S 019 Late Effects of Tuberculosis N 0020 Typhoid Fever S 0021 Paratyphoid Fever A S 0022 Paratyphoid Fever B S 0023 Paratyphoid Fever C S 024 Glanders Y 025 Melioidosis
    [Show full text]
  • (COVID-19) Outbreak: an Experience from Daegu, Korea
    Infect Chemother. 2020 Jun;52(2):226-230 https://doi.org/10.3947/ic.2020.52.2.226 pISSN 2093-2340·eISSN 2092-6448 Editorial Changes in the Clinical Practice of Ophthalmology during the Coronavirus Disease 2019 (COVID-19) Outbreak: an Experience from Daegu, Korea Areum Jeong 1,2 and Min Sagong 1,2 1Department of Ophthalmology, Yeungnam University College of Medicine, Daegu, Korea 2Yeungnam Eye Center, Yeungnam University Hospital, Daegu, Korea Received: May 24, 2020 The world has been hit hard by the coronavirus disease 2019 (COVID-19) pandemic. Korea Accepted: May 25, 2020 experienced a surge of patients because of a mass infection in an obscure religious group Corresponding Author: in Daegu. With our experience from hospitals in Daegu, the epicenter of the COVID-19 Min Sagong, MD outbreak in Korea, we suggest the strategies that should be followed in order to reduce the Department of Ophthalmology, Yeungnam transmission and assess the risk in the field of ophthalmology. University College of Medicine, 170 Hyunchungro, Nam-gu, Daegu 42415, Korea. Tel: +82-53-620-3443 Fax: +82-53-626-5936 TRANSMISSION OF SEVERE ACUTE RESPIRATORY E-mail: [email protected] SYNDROME CORONAVIRUS 2 (SARS-CoV-2) Copyright © 2020 by The Korean Society We are still learning about how SARS-CoV-2 spreads. The virus is mainly transmitted of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society person-to-person, particularly among those who are in close contact with one another for AIDS within approximately 6 feet. Moreover, it may be possible that a person contract COVID-19 This is an Open Access article distributed by touching a surface that has the virus on it and then touching their own mouth, nose, or under the terms of the Creative Commons possibly their eyes.
    [Show full text]
  • Eye Infections
    CLINICAL Approach Taking a Look at Common Eye Infections John T. Huang, MD, FRCSC and Peter T. Huang, MD, FRCSC he acutely red eye is often seen first by the primary-care physician. The exact Tcause may be difficult to determine and may cause some concern that a serious ocular condition has been missed. Thorough history and clinical examination will help delineate the final diagnosis. When there are doubts, prompt referral to an oph- thalmologist can prevent serious consequences. Often, the most likely diagnosis of an acutely red eye is acute conjunctivitis. In the first day, an acute bacterial infection may be hard to differentiate from viral, chlamydial and noninfectious conjunctivitis and from episcleritis or scleritis. Below is a review of the most commonly seen forms of eye infections and treat- ments. Failure to improve after three to five days should lead to a re-evaluation of the patient and appropriate referral where necessary. CHRONIC BLEPHARITIS Clinical: Gritty burning sensation, mattering, lid margin swelling and/or scaly, flaky debris, mild hyperemia of conjunctiva; may have acne rosacea or hyperkeratotic dermatitis (Figure 1). Anterior: Staphylococcus aureus (follicles, accessory glands); posterior (meibomian glands). Treatment: • Lid scrubs (baby shampoo, lid-care towellettes, warm compresses). Figure 1. Chronic blepharitis. There may be localized sensitivity to the shampoo or the components of the solution in the towellettes (e.g., benzyl alcohol). • Hygiene is important for the treatment and management of chronic blepharitis. Topical antibiotic-corticosteroid combinations (e.g., tobramycin drops, tobramycin/dexamethasone or sulfacetamide sodium-prednisolone acetate). Usage of these medications is effective in providing symptomatic relief, as the inflammatory component of the problem is more effectively dealt with.
    [Show full text]
  • Diagnosis and Treatment of Neurotrophic Keratopathy
    An Evidence-based Approach to the Diagnosis and Treatment of Neurotrophic Keratopathy ACTIVITY DIRECTOR A CME MONOGRAPH Esen K. Akpek, MD This monograph was published by Johns Hopkins School of Medicine in partnership Wilmer Eye Institute with Catalyst Medical Education, LLC. It is Johns Hopkins School of Medicine not affiliated with JAMA medical research Baltimore, Maryland publishing. Visit catalystmeded.com/NK for online testing to earn your CME credit. FACULTY Natalie Afshari, MD Mina Massaro-Giordano, MD Shiley Eye Institute University of Pennsylvania School of Medicine University of California, San Diego Philadelphia, Pennsylvania La Jolla, California Nakul Shekhawat, MD, MPH Sumayya Ahmad, MD Wilmer Eye Institute Mount Sinai School of Medicine Johns Hopkins School of Medicine New York, New York Baltimore, Maryland Pedram Hamrah, MD, FRCS, FARVO Christopher E. Starr, MD Tufts University School of Medicine Weill Cornell Medical College Boston, Massachusetts New York, New York ACTIVITY DIRECTOR FACULTY Esen K. Akpek, MD Natalie Afshari, MD Mina Massaro-Giordano, MD Professor of Ophthalmology Professor of Ophthalmology Professor of Clinical Ophthalmology Director, Ocular Surface Diseases Chief of Cornea and Refractive Surgery University of Pennsylvania School and Dry Eye Clinic Vice Chair of Education of Medicine Wilmer Eye Institute Fellowship Program Director of Cornea Philadelphia, Pennsylvania Johns Hopkins School of Medicine and Refractive Surgery Baltimore, Maryland Shiley Eye Institute Nakul Shekhawat, MD, MPH University of California,
    [Show full text]